retina/vitreous

Host: Jennifer Caudle, DO

Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.

Host: Jennifer Caudle, DO

Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.

Host: Jennifer Caudle, DO

Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.

Host: Jennifer Caudle, DO

Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.

Host: Jennifer Caudle, DO

Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.

Host: Roy Levit, MD
Guest: Alan Ruby, MD

The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in the eye that needs treatment? How soon after surgery will patients see a change in their vision? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses ways to maximize the overall visual outcome for patients with diabetic retinopathy. How can diabetic retinopathy be prevented? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Alan Ruby, MD

The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in the eye that needs treatment? How soon after surgery will patients see a change in their vision? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses ways to maximize the overall visual outcome for patients with diabetic retinopathy. How can diabetic retinopathy be prevented? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Alan Ruby, MD

The eyes can yield clues to vascular issues elsewhere in the body. How can the two forms of diabetic retinopathy, which are non-proliferative and proliferative, affect vision, and how might retinopathy be associated with somatic effects resulting from diabetes? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses the correlation between diabetic retinopathy and complications throughout the body. Can tight control of diabetes affect the progression or regression of retinopathy? What can physicians caring for patients with diabetes do to identify vision changes early on, and potentially reduce the risk of later complications? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Alan Ruby, MD

The eyes can yield clues to vascular issues elsewhere in the body. How can the two forms of diabetic retinopathy, which are non-proliferative and proliferative, affect vision, and how might retinopathy be associated with somatic effects resulting from diabetes? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses the correlation between diabetic retinopathy and complications throughout the body. Can tight control of diabetes affect the progression or regression of retinopathy? What can physicians caring for patients with diabetes do to identify vision changes early on, and potentially reduce the risk of later complications? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Saad Shaikh, MD

Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Saad Shaikh, MD

Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Saad Shaikh, MD

Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Allen Verne, MD

What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Allen Verne, MD

What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Allen Verne, MD

What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.

Host: Roy Levit, MD
Guest: Allen Verne, MD

What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.

Host: Steven Edelman, MD
Guest: Paul Tornambe, MD

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Join host Dr. Steven Edelman and his guest, ophthalmologist Dr. Paul Tornambe, an instructor in the departments of ophthalmology and family practice at the University of California, San Diego, as they discuss early diagnosis, tele-health and the exciting new VEGF inhibitors treatment of diabetic macular edema.

Host: Steven Edelman, MD
Guest: Paul Tornambe, MD

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in American adults. Join host Dr. Steven Edelman and his guest, ophthalmologist Dr. Paul Tornambe, an instructor in the departments of ophthalmology and family practice at the University of California, San Diego, as they discuss early diagnosis, tele-health and the exciting new VEGF inhibitors treatment of diabetic macular edema.

Host: Jennifer Shu, MD, FAAP
Guest: David Abramson, MD

Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.

Host: Jennifer Shu, MD, FAAP
Guest: David Abramson, MD

Survival rates for retinoblastoma now approach 100 percent, but in years past, enucleation was the only sure way to cure this rare pediatric malignancy. We're now seeing advances in chemotherapy that not only spare the child's eye, but can preserve vision as well. What makes this chemotherapy regimen so effective, and how can we build on its effectiveness to enhance the vision and the livelihood of children affected by retinoblastoma? Dr. David Abramson, chief of the ophthalmic oncology service at Memorial Sloan-Kettering Cancer Center in New York, joins host Dr. Jennifer Shu to talk about the breadth of retinoblastoma research that has helped us take important strides toward remediation of this disease.